

James N Fleming

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2244172/publications.pdf>

Version: 2024-02-01

45
papers

590
citations

686830

13
h-index

676716

22
g-index

47
all docs

47
docs citations

47
times ranked

930
citing authors

#	ARTICLE	IF	CITATIONS
1	A Critical Analysis of the Specific Pharmacist Interventions and Risk Assessments During the 12-Month TRANSafe Rx Randomized Controlled Trial. <i>Annals of Pharmacotherapy</i> , 2022, 56, 685-690.	0.9	2
2	Review and Evaluation of mHealth Apps in Solid Organ Transplantation: Past, Present, and Future. <i>Transplantation Direct</i> , 2022, 8, e1298.	0.8	7
3	Substance use screening in transplant populations: Recommendations from a consensus workgroup. <i>Transplantation Reviews</i> , 2022, 36, 100694.	1.2	2
4	The impact of pretransplant opioid exposure on healthcare utilization and costs in kidney transplant. <i>Pharmacotherapy</i> , 2021, 41, 6-13.	1.2	4
5	Impact of a pharmacist-led, mHealth-based intervention on tacrolimus trough variability in kidney transplant recipients: A report from the TRANSafe Rx randomized controlled trial. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1287-1293.	0.5	14
6	Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 776-784.	2.2	22
7	Survey-based assessment of shifting trends in first solid organ transplant pharmacist jobs. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 1144-1153.	0.5	1
8	Impact of Anesthesiologist Experience on Early Outcomes in Adult Orthotopic Liver Transplantation. <i>Transplantation Proceedings</i> , 2021, 53, 1665-1669.	0.3	0
9	Significant hospitalization cost savings to the payer with a pharmacist-led mobile health intervention to improve medication safety in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3428-3435.	2.6	14
10	Dosing Requirements of Extended-Release Tacrolimus (Astagraf XL) in African American Kidney Transplant Recipients Converted from Immediate-Release Tacrolimus (AAAKTRS). <i>Therapeutic Drug Monitoring</i> , 2020, 42, 415-420.	1.0	0
11	Understanding and using AlloSure donor-derived cell-free DNA. <i>Biophysical Reviews</i> , 2020, 12, 917-924.	1.5	7
12	Observations from a systematic review of pharmacist-led research in solid organ transplantation: An opinion paper of the American College of Clinical Pharmacy Immunology/Transplantation Practice and Research Network. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 1344-1354.	0.5	4
13	Impact of a multidisciplinary multimodal opioid minimization initiative in kidney transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e14006.	0.8	15
14	Preliminary assessment of safety and adherence to a once-daily immunosuppression regimen in kidney transplantation: Results of a randomized controlled pilot study. <i>Clinical Transplantation</i> , 2020, 34, e13844.	0.8	5
15	The effect of targeted insurer-mandated prescription monitoring on opioid prescribing patterns. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 559-564.	0.7	2
16	Using informatics and mobile health to improve medication safety monitoring in kidney transplant recipients. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1143-1149.	0.5	25
17	Protocol-based nurse coordinator management of ambulatory tacrolimus dosing in de novo renal transplant recipients: A single-center experience with a large African American population. <i>Clinical Transplantation</i> , 2019, 33, e13701.	0.8	1
18	The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study. <i>Transplant International</i> , 2019, 32, 84-94.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Association of Pretransplantation Opioid Use with Graft Loss or Death in Liver Transplantation Patients with Model of End-Stage Liver Disease Exceptions. <i>Journal of the American College of Surgeons</i> , 2018, 226, 651-659.	0.2	8
20	Morbid obesity and functional status as predictors of surgical complication after renal transplantation. <i>American Journal of Surgery</i> , 2018, 215, 663-668.	0.9	13
21	Incidence and impact of adverse drug events contributing to hospital readmissions in kidney transplant recipients. <i>Surgery</i> , 2018, 163, 430-435.	1.0	7
22	It is time for board certification in transplant pharmacotherapy. <i>American Journal of Transplantation</i> , 2018, 18, 2370-2371.	2.6	4
23	Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSafe Rx Study Protocol. <i>JMIR Research Protocols</i> , 2018, 7, e59.	0.5	15
24	Effectiveness of an Evidence-Based Induction Therapy Protocol Revision in Adult Kidney Transplant Recipients. <i>Pharmacotherapy</i> , 2017, 37, 692-699.	1.2	3
25	The Impact of Health Care Appointment Non-Adherence on Graft Outcomes in Kidney Transplantation. <i>American Journal of Nephrology</i> , 2017, 45, 91-98.	1.4	47
26	Liver Transplantation in the Obese Cirrhotic Patient. <i>Transplantation</i> , 2017, 101, 2288-2296.	0.5	67
27	Development of a Predictive Model for Drug-Related Problems in Kidney Transplant Recipients. <i>Pharmacotherapy</i> , 2017, 37, 159-169.	1.2	9
28	Valganciclovir (<sc>VGCV</sc>) followed by cytomegalovirus (<sc>CMV</sc>) hyperimmune globulin compared to <sc>VGCV</sc> for 200 days in abdominal organ transplant recipients at high risk for <sc>CMV</sc> infection: A prospective, randomized pilot study. <i>Transplant Infectious Disease</i> , 2017, 19, e12779.	0.7	5
29	Opioid and opioid substitution therapy in liver transplant candidates: A survey of center policies and practices. <i>Clinical Transplantation</i> , 2017, 31, e13119.	0.8	25
30	Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 2931-2938.	0.5	57
31	Mobile Health Technology in Transplantation. , 2017, , 63-85.		0
32	Depression, Resource Utilization, and Outcomes Following Liver Transplant. <i>Progress in Transplantation</i> , 2016, 26, 270-276.	0.4	8
33	Incidence, risk factors, and outcomes of opportunistic infections in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2016, 20, 44-48.	0.5	21
34	Predicting and preventing readmissions in kidney transplant recipients. <i>Clinical Transplantation</i> , 2016, 30, 779-786.	0.8	26
35	A randomized, prospective comparison of transition to sirolimus-based <sc>CNI</sc> minimization or withdrawal in African American kidney transplant recipients. <i>Clinical Transplantation</i> , 2016, 30, 528-533.	0.8	8
36	Optimizing finite resources: Pharmacist chart reviews in an outpatient kidney transplant clinic. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, 613-620.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients. <i>Transplantation</i> , 2015, 99, 1499-1505.	0.5	35
38	Clinical and Economic Outcomes Associated with Medication Errors in Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 960-966.	2.2	30
39	The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C. <i>Clinical Transplantation</i> , 2014, 28, 862-868.	0.8	22
40	Racial Comparisons of Everolimus Pharmacokinetics and Pharmacodynamics in Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 753-759.	1.0	6
41	Are Thiazide Diuretics Safe and Effective Antihypertensive Therapy in Kidney Transplant Recipients. <i>American Journal of Nephrology</i> , 2013, 38, 285-291.	1.4	22
42	Effect of standardized medication-order forms on medication errors after liver or kidney transplantation. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 916-917.	0.5	1
43	Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients. <i>Transplant International</i> , 2010, 23, 500-505.	0.8	8
44	Hepatorenal Syndrome: A Comprehensive Overview for the Critical Care Nurse. <i>Critical Care Nursing Clinics of North America</i> , 2010, 22, 351-368.	0.4	1
45	Novel Strategies for Immune Monitoring in Kidney Transplant Recipients. <i>Advances in Chronic Kidney Disease</i> , 2010, 17, e63-e77.	0.6	6